Development of PHVS719: an Oral Extended-Release Bradykinin B2 Receptor Antagonist to Prevent Hereditary Angioedema Attacks

Lesage A.1, Gibson C.2, Knolle J.1, Groen K.3, Crabbé R.4, Lu P.5

1Pharvaris GmbH, Zug, Switzerland, 2AnalytiCon Discovery GmbH, Postdam, Germany, 3Dr. Reddy’s Laboratories, India, 4RC Consultancy, Bassins, Switzerland, 5Pharvaris Inc., Lexington, MA, United States of America

Introduction

• Excess bradykinin is the cause of clinical signs and symptoms of hereditary angioedema (HAE) attacks.
• Efficacy and tolerability of bradykinin B2-receptor antagonism for treatment of HAE attacks were proven in clinical studies and confirmed in >10 years of experience in real-world practice.
• PHA022121 (PHA121) is a novel, orally-available bradykinin B2 receptor antagonist that is 20-25-fold more potent than icatibant at competing with bradykinin at the endogenous human B2 receptor, as evaluated in in vitro and ex vivo preclinical studies.
• In an in vivo bradykinin challenge study in humans oral PHA121 inhibited effects of bradykinin with higher potency and longer extended duration than subcutaneous icatibant.
• PHA121 is being developed in two formulations specifically designed to meet the requirements for oral on-demand treatment of HAE attacks (PHVS416), as well as for oral prophylactic treatment to prevent HAE attacks (PHVS719).

Methods

• Colonic absorption of PHA121 was investigated in rats receiving a single dose of 2 mg/kg PHA121 either by oral gavage or intracolonic administration via a catheter surgically implanted into the ascending colon.
• Mass balance and absolute bioavailability in humans were assessed in an open-label, single-dose mass balance study with a microtracer dose of [14C]-PHA022121 in healthy subjects.
• An in vitro dissolution experiment was conducted with PHVS719 in conditions mimicking fasted and fed gastrointestinal environments to measure dissolution of the active ingredient, PHA121, over time.
• Pharmacokinetics of an extended-release (XR) formulation of PHA121 (PHVS719) under fasting or fed conditions was evaluated in an open-label, single-dose, randomized, five-period, five-sequence, crossover, exploratory Phase 1 study.

Results

• Direct intracolonic dosing of PHA121 resulted in a good systemic exposure to PHA121, comparable to that observed after oral administration, thus confirming the colonic absorption.
• In humans, absolute availability of PHA121 after oral administration was 57%, with approximately 3.2% of PHA121 excreted via feces.
• Administration of PHVS416 resulted in rapid clinically relevant exposure of PHA121 above EC50 (13.8 ng/ml) within 30 minutes. Administration of PHVS719 40 mg under fasted condition yielded exposure EC50 by ~2 hours and maintained it for ~20 hours. The overall exposure was not affected by food.
• The 24-hour area-under-the-curve (AUC0-24) exposure of PHA121 after 1 dose of PHVS719 40 mg is comparable to that observed in Phase 1 studies with PHVS416 soft capsules dosed 20 mg bid with food.

Conclusions

• PHVS719, the extended-release formulation of PHA121, meets the required characteristics for prophylactic treatment to prevent HAE attacks.
• The almost complete colonic absorption of PHA121 results into durable therapeutic exposure for ~24 hours, supporting once-daily dosing for prophylaxis.
• The safety and efficacy of PHA121 as active ingredient for the prevention of HAE attacks are being evaluated in the Phase 2 CHAPERON-2 proof-of-concept clinical trial (PHVS416 formulation, bid).

The FDA has placed a clinical hold on the clinical trials of PHVS71914 in the U.S. Regulators in no U.S. countries have been notified of U.S. clinical hold. Visit https://a.pharvaris.com/ for the latest information and updates.

References